Novo CEO Says Drugmaker Has More to Do to Win Over Investors

Novo Nordisk A/S Chief Executive Officer Mike Doustdar said the company must do more to build investor confidence as the Ozempic maker faces a patent cliff for its biggest drugs...

By Ashleigh Furlong and Naomi Kresge · Bloomberg

Novo Nordisk A/S Chief Executive Officer Mike Doustdar said the company must do more to build investor confidence as the Ozempic maker faces a patent cliff for its biggest drugs at the beginning of the next decade.